503B Compounding Pharmacy

Latest News


Latest Videos


CME Content


More News

According to the indictment, from May 2014 to September 2016, the involved parties allegedly recieved kickbacks for the referral of TRICARE and DOL beneficiaries to obtain expensive compound drugs.

Each year, more than 8 million U.S. health care personnel are potentially exposed to hazardous medications. Acute and chronic health effects have been reported, including headaches, ocular problems, rashes, hair loss, adverse reproductive health, and increased cancer risk.

Officials with the FDA have issued 2 final guidance documents to help implement the 2018 Compounding Policy Priorities Plan, which explain the agency’s policies on the “essentially a copy” provisions of sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

Pharmacists should be aware of what components they need to address to comply in order to prep themselves for USP standards.